Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Shares of Aerie Pharmaceuticals Inc (NASDAQ: AERI) surged more than 65 percent in Wednesday's after-hours session.
The stock was responding to news about its Phase 3 study of Roclatan having met its primary efficacy endpoint.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
According to a press release, Roclatan managed to prove statistically superior to each of its components, including the company’s Rhopressa (netarsudil ophthalmic solution) 0.02 percent and the market leading prostaglandin analogue (PGA) latanoprost, in the treatment of patients with maximum baseline intraocular pressures (IOPs) ranging from over 20 to under 36 mmHg (millimeters of mercury).
Roclatan made IOP 1 to 3 mmHg lower than latanoprost or Rhopressa could make it on their own.
On Friday, September 9, Benzinga Pro alerted users about "Unusual Options Activity in Aerie Pharma for Second Day in a Row. Call Activity Suggests Trader Betting Underlying Stock Will Be Over $34 Within Next 60 Days."
Shares traded recently at $34.89, up 64.8 percent after hours. The stock closed at $21.13.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.